By Devika Patel
Knoxville, Tenn., Dec. 5 – Credit Suisse AG, London Branch, priced $247,000 of 0% accelerated barrier notes due Dec. 3, 2021 linked to the SPDR S&P Biotech exchange-traded fund, according to a 424B2 filing with the Securities and Exchange Commission.
If the fund finishes at or above the initial level, the payout at maturity will be par plus 101.25% of the return.
If the fund falls by up to the 40% knock-in level, the payout will be par.
Otherwise, investors will lose 1% for each 1% decline.
Credit Suisse Securities (USA) LLC is the agent.
| Issuer: | Credit Suisse AG, London Branch
|
| Issue: | Accelerated barrier notes
|
| Underlying ETF: | SPDR S&P Biotech
|
| Amount: | $247,000
|
| Maturity: | Dec. 3, 2021
|
| Coupon: | 0%
|
| Price: | Par
|
| Payout at maturity: | Par plus 101.25% of any fund gain; par if fund falls by up to 40%; otherwise, 1% loss for each 1% decline
|
| Initial level: | $62.67
|
| Knock-in level: | $37.602, 60% of initial level
|
| Pricing date: | Nov. 30
|
| Settlement date: | Dec. 5
|
| Agent: | Credit Suisse Securities (USA) LLC
|
| Fees: | 0.65%
|
| Cusip: | 22548QNE1
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
